

# CURRICULUM VITAE

## Marco Arrese, MD, FACP, FAASLD

### PERSONAL INFORMATION

Date of Birth: October 23, 1964  
Place of Birth: Santiago, Chile  
Citizenship: Chilean and Spanish

### Professional Address and Contact information:

Departamento de Gastroenterología  
Pontificia Universidad Católica de Chile  
Diagonal Paraguay #362  
8330077  
Santiago  
CHILE  
+56-9-6/2288523 (cellular)  
+ 56-2-23543822 (Secretary)  
Email: [marrese@med.puc.cl](mailto:marrese@med.puc.cl)

### EDUCATION:

#### Graduate/Professional:

- M. D., University of Chile, School of Medicine (1987)

#### Post-Doctoral Training :

- Internal Medicine Residency, Catholic University of Chile, School of Medicine (1988-1991)
- Chief Resident (1990-1991), Catholic University of Chile, School of Medicine (1991)
- Gastroenterology Fellowship, Department of Gastroenterology, Catholic University of Chile, School of Medicine (1991-1993)
- Research Fellowship (Experimental Hepatology), Supported by the Fogarty International Center, NIH, Bethesda, MD, USA. Gastroenterology/Hepatology

section, Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA (1995-1997)

**CURRENT POSITION:**

Professor of Medicine  
Head,  
Department of Gastroenterology  
School of Medicine  
Pontificia Universidad Católica de Chile (<http://medicina.uc.cl/>)

(Faculty member since 1993, Professor of Medicine since 2009, Department 's Head since 2010)

**FORMER ACADEMIC APPOINTMENTS:**

- **Instructor of Medicine**, Department of Gastroenterology, Catholic University of Chile, School of Medicine (1993-1995)
- **Research Fellow**, Gastroenterology/Hepatology section, Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA (1995-1997)
- **Instructor of Medicine**, Department of Gastroenterology, Catholic University of Chile, School of Medicine (1997-1999)
- **Assistant Professor of Medicine**, Department of Gastroenterology, Catholic University of Chile, School of Medicine (1999-2002)
- **Associate Professor of Medicine**, Department of Gastroenterology, Catholic University of Chile, School of Medicine (2002-2008)
- **Director**, Office for Medical Research Affairs, Catholic University of Chile, School of Medicine (2004-2008)
- **Director**, Research Ethics Committee (IRB equivalent) , Catholic University of Chile, School of Medicine (2004-2008)

**GOOD CLINICAL PRACTICE TRAINING:**

- AE/SAE Training for Clinical Research Staff Medidata University (Nov 2010)
- Good Clinical Practice for Study Site Personnel Medidata University (Nov 2010)

- GCP courses, Collaborative Institutional Training Initiative (CITI Program, Dec 2016)

## **PROFESSIONAL SOCIETIES**

- Chilean Society of Internal Medicine (since 1988)
- Chilean Society of Gastroenterology (member since 1991, Vice-president 2012-2014, President [term 2014-2016])
- Chilean Hepatology Association (since 1993, Board of Directors since 1998, Vice-President 2000-2002. President, 2002-2004)
- Latin-American Society for the Study of the Liver (1999-present)
- Peruvian Society of Gastroenterology (2000-present)
- Paraguayan Society of Gastroenterology (Corresponding, 2010)
- American College of Physicians (Associate member, 1988-1991, Fellow 2014-present)
- American Association for the Study of Liver Diseases (Trainee member, 1996-1997, International member 2004-present)
- International Association for the Study of the liver (International member 2007-present)

## **HONORS AND AWARDS**

- Scholarship from Catholic University of Chile School of Medicine (support of Internal Medicine Residency), 1988.
- Scholarship from Catholic University of Chile School of Medicine (support of Gastroenterology Fellowship), 1991.
- "Reina Sofía" award, 1991 (educational grant from Spanish government)
- Catholic University of Chile, Research Committee Prize for best fellow research project. "Ursodeoxycholic acid and ethynylestradiol-induced cholestasis", 1995
- "Presidente de la Republica" Award 1995 (educational grant from International Chilean Cooperation Agency)
- International Research Fellowship Award, 1995 John E. Fogarty International Center, NIH, Bethesda, U.S.A. 5 F05 TW05082-02
- 1998 HOESCHT-FOUNDATION PRIZE to the paper: "Trauner M, Arrese M, Soroka C, Ananthanarayanan M, Koeppl TA, Schlosser S, Suchy FJ, Keppler D, Boyer JL. The rat canalicular conjugate export pump (Mrp2) is down-

regulated in intrahepatic and obstructive cholestasis. Gastroenterology 1997;113:255-64.", Graz, Austria.

- Young Investigator Award, Chilean Society of Gastroenterology, 1999
- Chilean National Academy of Medicine Award (Research Achievements) 2008
- Young Investigator Award 2009, Catholic University of Chile School of Medicine,
- Best scientific abstract, Annual meetings of the Chilean Society of Gastroenterology, 2008-2010, 2014
- Senior Investigator Award 2015, Catholic University of Chile School of Medicine,

## **RESEARCH INTERESTS**

- Molecular regulation of hepatobiliary transport systems in cholestatic disease. Mechanisms of cell injury and progression in cholestatic and fatty liver disease. Comorbidities in fatty liver disease.

## **RESEARCH GRANTS AS PI (SINCE 2002)**

1. 2002-2004 Principal Investigator, FONDECYT Project #1020641 "LIVER INJURY IN THE STEATOTIC LIVER: ASSESSMENT OF LIVER DAMAGE SUSCEPTIBILITY IN GENETICALLY OBESE MICE" (US\$200000)
2. 2005-2008 Principal Investigator, FONDECYT Project #1050780 DETERMINANTS AND MODULATION OF EXPERIMENTAL LIVER INJURY (US\$200000)
3. 2008/2011 Principal Investigator, FONDECYT Project #1080170 "NON-ALCOHOLIC FATTY LIVER: EXPERIMENTAL AND CLINICAL STUDIES ON THE ROLE OF BILE ACIDS, ENDOPLASMIC RETICULUM STRESS AND ADIPOKINES" (US\$300000)
4. 2010-2013 Principal Investigator, Associative Scientific Project ACT 79, Conicyt "BIOMEDICAL IMAGING IN OBESITY: FROM CELLULAR MECHANISMS TO CLINICAL APPLICATIONS"
5. 2011-2015, Principal Investigator, FONDECYT Project 1110455 "EXPLORING NEW PATHOPHYSIOLOGICAL PATHWAYS IN NON-ALCOHOLIC FATTY LIVER DISEASE" [4 YEARS, US\$400000]

6. 11/2013-present Senior Investigator [<http://www.carechileuc.cl/>] CARE Chile UC – CENTER FOR AGING AND REGENERATION Pontificia Universidad Católica de Chile [5 YEARS, US\$250000].
7. 2015–2018 Principal Investigator, FONDECYT Project 1115327 “LIVER INJURY IN NON-ALCOHOLIC FATTY LIVER DISEASE: EXPLORING NOVEL MODULATORS AND MARKERS” [4 YEARS, US\$400000]

### CLINICAL INTERESTS

- Cholestatic liver disease, Fatty liver disease, liver transplantation, cirrhosis and its complication

### TEACHING ACTIVITIES

- Continued teaching activities with GI and Hepatology fellows in the Department of Gastroenterology, PUC School of Medicine
- Undergraduate teaching at PUC School of Medicine (GI course and lectures 3<sup>rd</sup>, 4<sup>th</sup> and 5<sup>th</sup> year medical students), (1998-present)

### TRAINEES

<b>Dates</b>	<b>Trainee (Current position)</b>	<b>Project/Publication</b>
2000-2001	Alejandro Soza, MD Associate Prof., PUC School of Medicine	Increased orocecal transit time in patients with non-alcoholic fatty liver disease Dig Dis Sci. 2005 Jun;50(6):1136-40.
2001-2002	Arnoldo Riquelme, MD Associate Prof., PUC School of Medicine	Predictors of NASH in obese patients undergoing gastric bypass. Obesity Surgery 2005;15:1148-53.
2003-2004	Paula Vial, MD Gastroenterologist, Clinica Alemana (Chile)	Pentoxifylline does not prevent neither liver damage nor early profibrogenic events in a rat model of non-alcoholic steatohepatitis Annals of Hepatology 2006;5;25-27
2004-2005	Patricio Ibañez, MD Asstistan Prof., PUC School of Medicine	Effect of losartan on early liver fibrosis development in a rat model of non-alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology 2007 Jun;22(6):846-51
2005-2006	Cristián Cerda, MD Gastroenterologist, Military Hospital (Chile)	Non-alcoholic fatty liver disease in patients with Polycystic Ovary Syndrome Journal of Hepatology 2007 Sep;47(3):412-7.
2007-	Leyla Nazal, MD	Hypoadiponectinemia and its association

2008	Gastroenterologist, Chief of GI, Air force hospital (Chile)	with liver fibrosis in morbidly obese patients. <i>Obes Surg</i> 2010;20:1400-1407.
2008-2010	Karla Vasquez, BS Research Assistant University fo Chile School of Medicine	ER stress and NAFLD
2011-2012	Paula Rey, MD Gastroenterologist PUC School of Medicine	Minimal Hepatic Encephalopathy in compensated cirrhosis
2012-2014	Pablo Quintero, PhD MBA student, Sydney Australia	Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion. <i>J Physiol Biochem</i> 2014;70:667-674.
2008-present	Juan Pablo Arab, MD Gastroenterologist, PUC School of Medicine Research Fellow, Mayo Clinic, Rochester, USA	Multiple roles and publications (see reference list for details)
2013-2016	Daniel Cabrera, PhD Post-doctoral fellow PUC School of Medicine	Andrographolide Ameliorates Inflammation and Fibrogenesis and Attenuates Inflammasome Activation in Experimental Non-Alcoholic Steatohepatitis. <i>Scientific Reports</i> 2017;7:349
2013-2015	Alex Ruiz, MD Hepatologist, Austral University, Valdivia (Chile)	Diet-Induced Nonalcoholic Fatty Liver Disease Is Associated with Sarcopenia and Decreased Serum Insulin-Like Growth Factor-1. <i>Dig Dis Sci.</i> 2016 Aug 29
2013-2017	Rodrigo Cruz, MD Gastroenterologist Clinica Davila, Santiago	Chronic Intermittent Hypoxia in NAFLD

#### **INTERNATIONAL INVITED LECTURES AND ROUND TABLE MODERATOR ROLE**

1. **Lecture:** *Clinical course of NAFLD: Risk factors for disease progression and mortality*, Postgraduate Course, Hepatologia do Milênio 2017 Salvador, Brasil, July 2017
2. **Lecture:** *New treatments for NASH: the landscape*, Postgraduate Course, Hepatologia do Milênio 2017 Salvador, Brasil, July 2017
3. **Lecture:** *Approach to NASH in my daily clinical practice*, Postgraduate Course, Hepatologia do Milênio 2017 Salvador, Brasil, July 2017
4. **Lecture:** *Comorbidities in Non Alcoholic Fatty Liver Disease*, Metabolic Health initiative, Emory University School of Medicine, Atlanta, USA, February 2017

5. **Lecture:** Bile Acids & Non Alcoholic Fatty Liver Disease: insights from animal models. Department of Medicine, Emory University School of Medicine, Atlanta, USA, February 2017
6. **Lecture:** Comorbidities in Non Alcoholic Fatty Liver Disease, IV Basque-Chilean Biomedical Research Meeting, Bilbao, Spain, December 2016
7. **Lecture:** Bile Acids & Non Alcoholic Fatty Liver Disease: Molecular insights and therapeutic perspectives, IV Basque-Chilean Biomedical Research Meeting, Bilbao, Spain, December 2016
8. **Lecture:** New paradigms in the treatment of Cholestasis, Latin American Hepatology meeting, Santiago, Chile, September 2016
9. **Lecture:** *On being an academic hepatologist: A Latin-American perspective*, Latin American Hepatology meeting, Santiago, Chile, September 2016
10. **Early Morning Workshop (moderator):** When to perform liver biopsy in NASH. International liver congress, Barcelona, Spain, April 2016
11. **Lecture:** Pathophysiology of Non-alcoholic fatty liver disease, 7th Crossing Borders Seminar, Groningen, The Netherlands, January 2016
12. **Lecture:** Non-alcoholic fatty liver disease, Internal Medicine Meeting, Buenos Aires Argentina, September 2016
13. **Lecture:** Diet and non-alcoholic fatty liver disease Chilean-Basque Biomedical research meeting, Bilbao, Spain, December 2014
14. **Lecture:** Non-alcoholic fatty liver disease: Science and practice. Chilean-Basque Biomedical research meeting, Bilbao, Spain, December 2014
15. **Lecture:** Pathophysiological aspects of Non-alcoholic fatty liver disease Gastrointestinal Physiology Symposium, Argentinian Society of Clinical Research, Mar del Plata Argentina, November 2014
16. **Lecture:** Toxic cholestasis: mechanisms and practical management Meeting of the Latin American Association for the study of the Liver (ALEH), Meeting Acapulco, Mexico, September 2014
17. **Moderator:** Plenary lectures Autoimmune liver disease, ALEH, Meeting Acapulco, Mexico, September 2014
18. **Lecture:** Chronic Cholestasis: Current Concepts & Perspectives. National Meeting of the Peruvian Association for the study of the liver, Lima Perú, May 2014
19. **Lecture:** Treatment of drug-induced cholestasis Annual meeting Brazilian Society of hepatology, Río de Janeiro, Brazil, October 2013.
20. **Lecture:** Genetic Cholestasis XXII Meeting of the Latin American Association for the study of the Liver, Lima, Perú, September 2012
21. **Moderator:** Non Alcoholic Steatohepatitis, XXII Meeting of the Latin American Association for the study of the Liver, Lima, Perú, September 2012
22. **Lecture:** Nonalcoholic Fatty Liver disease, International Postgraduate Course on Liver Disease, IASL, Asunción, Paraguay, October 2011
23. **Lecture:** Cholestasis, International Postgraduate Course on Liver Disease, IASL, Asunción, Paraguay, October 2011
24. **Lecture:** Current views on Pathogenesis of Fatty Liver disease, Symposium: Cholestatic and metabolic liver disease: from basic science to clinical practice, Vienna, Austria, June 2012

25. **Lecture:** New perspectives in cholestasis XXI Meeting of the Latin American Association for the study of the Liver, Porto Alegre, Brazil, August 2010.
26. **Lecture:** Insulin resistance, hepatic steatosis and hepatitis C: a complex relationship with relevant clinical implications, Update in Hepatitis C, Cancun, Mexico, March 2010
27. **Lecture:** Nonalcoholic Fatty Liver disease, V FALK SYMPOSIUM, Lima Peru, September 2009
28. **Lecture:** UDCA in PBC, XX Meeting of the Latin American Association for the study of the Liver, Isla Margarita, Venezuela, September, 2008
29. **Moderator:** Parallel session, Human Cholestasis, 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, USA, Nov.01-06 2007
30. **Lecture:** Cholestasis during Pregnancy: rare diseases unmasked by pregnancy, Symposium on Liver & Pregnancy, Mexico City, Sept 27, 2006
31. **Lecture:** Intrahepatic Cholestasis of Pregnancy, Symposium on Liver & Pregnancy, Mexico City, Sept 27, 2006
32. **Lecture:** Nonalcoholic Fatty Liver disease: Pathogenesis and treatment, XI International Gastroenterology meeting, Tegucigalpa, Honduras, June 2006
33. **Lecture:** Primary Biliary Cirrhosis, International Gastroenterology meeting, Tegucigalpa, Honduras, June 2006
34. **Lecture:** Approach to Altered Liver tests, International Gastroenterology meeting, Tegucigalpa, Honduras, June 2006
35. **Lecture:** Autoimmune Hepatitis, International Gastroenterology meeting, Tegucigalpa, Honduras, June 2006
36. **Lecture:** Evaluation of liver fibrosis, Update in Gastroenterology and Hepatology, Lima Perú, August 2006
37. **Lecture:** Current and future treatment of Cholestatic liver diseases. Update in Gastroenterology and Hepatology, Lima Perú, August 2006
38. **Lecture:** Animal models of NASH, International Gastroenterology, Postgraduate Course, Lima Perú, July, 2003.
39. **Lecture:** Management of Primary Biliary Cirrhosis, International Gastroenterology, Postgraduate Course, Lima Perú, July 2003.
40. **Lecture:** Molecular mechanisms of cholestasis, International Gastroenterology, Postgraduate Course, Lima Perú, July, 2003.
41. **Lecture:** Fetal expression of basolateral bile acid transporters during maternal cholestasis. International Workshop on Bile acids and Pregnancy, Freiburg, Germany, May 2002
42. **Lecture:** Recent advances in Cholestasis, International Gastroenterology, Postgraduate course, ICA, Peru, April 2002.
43. **Lecture:** Nonalcoholic Fatty Liver disease, International Gastroenterology, Postgraduate Course, ICA, Peru, April 2002.
44. **Lecture:** Ursodeoxycholic acid in Cholestasis, International Gastroenterology Postgraduate course, ICA, Peru, April 2002.

#### **THESIS ASSESSMENT COMMITTEE MEMBERSHIP**

1. PhD thesis; Candidate: **R Rebolledo**, University Medical Center Groningen, The Netherlands (*Brain Death: From Inflammation to Metabolic Changes*)
2. PhD thesis; Candidate: **M Acuña**, Pontificia Universidad Católica de Chile. (*The p.Ala359Asp mutation in the enzyme acid sphingomyelinase as cause of Niemann-Pick disease type B: Genetic and biochemical study*)
3. PhD thesis; Candidate: **Elisa Balboa**, Pontificia Universidad Católica de Chile (*Relevance of mitochondrial dysfunction in oxidative damage and cell death in Niemann-pick disease type c: contribution of increased mln64-mediated cholesterol transport to mitochondria*)
4. PhD thesis; Candidate: **M. Tiebosch**, University Medical Center Groningen, The Netherlands (*Antioxidant adaptations in liver fibrogenesis*)
5. PhD thesis; Candidate: **Paulina Pettinelli**, School of Medicine, Universidad de Chile (*Role of transcription factors PPAR gamma and SREBP-1c in non-alcoholic fatty liver disease*)
6. PhD thesis; Candidate: **Rodrigo Castillo**, School of Medicine, Universidad de Chile (*Benefits of acute use of Omega 3 and vitamins C and E to avoid postoperative arrhythmia in cardiac surgery patients with extracorporeal circulation*)
7. PhD thesis; Candidate: **Juan Guillermo Gormaz**, School of Medicine, Universidad de Chile, (*Relationship of oxidative stress with the hepatic biosynthesis of long chain polyunsaturated fatty acids in obese insulin resistant wistar rats*)

## **SERVICES TO MEDICAL SOCIETIES**

### AASLD:

2010-2014 Member of the abstract review committee “Stetatosis and Steatohepatitis: Experimental” and “Alcohol: Clinical and experimental”

2003-2015 Scientific reviewer for Hepatology (AASLD’s official Journal): 68 times since 2003

### ALEH

2002-2014 Member of the abstract review committee, ALEH Biennial meeting

2013-2014 Chair, EASL-ALEH Clinical Practice Guidelines on Non-invasive tests for evaluation of liver disease severity and prognosis

### IASL

Associate Editor *Liver International* (IASL's official Journal)

CHILEAN SOCIETY OF GASTROENTEROLOGY

Abstract Reviewer (since 2002)  
Secretary for National Meetings (2000-2002)  
Scientific committee (2012-2016)  
Vice-president 2012-2014  
President 2014-2016

**Editorial Activities**

- Associate Editor *Liver International* 07/07-07/2012
- Associate Editor *Annals of Hepatology* 07/2010-to date
- Editorial Board Member *Journal of Hepatology* 01/05 – 12/08
- Editorial Board Member Gastroenterología y hepatología (Spain) 2003-2006
- Editorial Board Member Revista Medica de Chile 04/2004-to date
- Editorial Board Member *Gastroenterología Latinoamericana* 05/2008 - to date
- Editorial Board Member *Hepatology* 03/217 - to date
- Reviewer for the following journals:

*Hepatology, Journal of Hepatology, Liver International, GUT, Pediatric Research, Clinical Science (Lond.), Journal of Pharmacological and experimental Therapeutics, British Journal of Pharmacology, Biochemical Pharmacology, Journal of Gastroenterology and Hepatology, Liver International, American Journal of Physiology, Planta Medica, Annals of Hepatology, Drug Metabolism and Disposition, Clinics & Research in Hepatology and Gastroenterology, Plos One, Oncotarget and Alimentary Pharmacology and therapeutics.*

**PUBLICATIONS: 148** (78 Original Papers, 27 Review Articles, 5 Invited editorials, 10 invited commentaries, 18 case reports/case series, 3 letter to the editors, 2 essays)

### **ORIGINAL PAPERS (78)**

1. Cortés, V, Quezada N, Uribe S, Arrese M, Nervi F. Effect of cholecystectomy on hepatic fat accumulation and insulin resistance in nonobese Hispanic patients: a pilot study. *Lipids in Health and Disease* 2017;16:129
2. Cabrera D, Wree A, Povero D, Solís N, Hernandez A, et al. Andrographolide ameliorates inflammation and fibrogenesis and attenuates inflammasome activation in experimental non-alcoholic steatohepatitis. *Scientific reports* 2017;7:349
3. Arab JP, Hernández-Rocha C, Morales C, Vargas, JI, Solis N, Pizarro M, Robles, C, Sandoval D, Ponthus S, Benítez C, Barrera F, Soza A; Riquelme R, Arrese M. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the Chilean population. *Gastroenterol Hepatol.* 2017;40(6):388-394
4. Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX et al. Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study. *Gastroenterology* 2017;152:1078-1089
5. Solari S, Cancino A, Wolff R, Norero B, Vargas JI, Barrera F, Guerra JF, Martínez J, Jarufe N, Soza A, Arrese M, Benitez C. Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study. *Aliment Pharmacol Ther.* 2017;45:1225-1231
6. Norero B, Serrano CA, Sanchez-Fueyo A, Duarte I, Torres J, Ocquetau M, Barrera F, Arrese M, Soza A, Benítez C. Conversion to Mycophenolate Mofetil Monotherapy in Liver Recipients: Calcineurin Inhibitor Levels are Key. *Ann Hepatol.* 2017;16:94-106
7. Manríquez E, Tejos R, Rojas A, Pimentel E, Vega T, Achurra P, Avila R, Jarufe N, Crovari F, Arrese M, Marínez J. Postcholecystectomy diarrhea is a frequent problem? *Rev Chil Cir* 2017 (en prensa)
8. Arab JP, Barrera F, Gallego C, Valderas JP, Uribe S, Tejos C, Serrano C, Serrano C, Huete Á, Liberona J, Labbé P, Quiroga T, Benítez C, Irarrázaval P, Riquelme A, Arrese M. High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients. *Ann Hepatol.* 2016 Sep-Oct;15(5):721-8
9. Villarroel P, Mattar P, D'Espessailles A, Arrese M, Arreguin A, Fuentes C, Reyes M, Cifuentes M. Calcium sensing receptor effects in adipocytes and liver cells: Implications for an adipose-hepatic crosstalk. *Arch Biochem Biophys.* 2016 Oct 1;607:47-54
10. Cabrera D, Ruiz A, Cabello-Verrugio C, Brandan E, Estrada L, Pizarro M, Solis N, Torres J, Barrera F, Arrese M. Diet-Induced Nonalcoholic Fatty Liver Disease Is Associated with Sarcopenia and Decreased Serum Insulin-Like Growth Factor-1. *Dig Dis Sci.* 2016 Aug 2

11. Pollak F, Araya V, Lanas A, Sapunar J, Arrese M, Aylwin CG, Bezanilla CG, et al. [Second Consensus of the Chilean Society of Endocrinology and Diabetes about insulin resistance]. *Rev Med Chil* 2015;143:627-636.
12. Pizarro M, Solis N, Quintero P, Barrera F, Cabrera D, Rojas-de Santiago P, Arab JP, et al. Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis. *Liver Int* 2015;35:2129-2138.
13. Perez G, Kattan E, Collins L, Wright AC, Rybertt T, Gonzalez A, Sirhan M, et al. Assessment for learning: experience in an undergraduate medical theoretical course. *Rev Med Chil* 2015;143:329-336.
14. Cortés VA, Amigo L, Zanlungo S, Galgani J, Robledo F, Arrese M, Bozinovic F, Nervi, F. Metabolic effects of cholecystectomy: gallbladder ablation increases basal metabolic rate through G-protein coupled bile acid receptor Gpbar1-dependent mechanisms in mice. *PLoS One*. 2015 Mar 4;10(3):e0118478
15. Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Caliz I, Gonzalez-Jimenez A, Ulzurrun E, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. *Gastroenterology* 2014;147:109-118 e105.
16. Quintero P, Pizarro M, Solis N, Arab JP, Padilla O, Riquelme A, Arrese M. Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion. *J Physiol Biochem* 2014;70:667-674.
17. Martinez J, Bachler JP, Moisan F, Torres J, Duarte I, Perez RM, Benitez C, et al. Outcomes using two preservation solutions (UW/HTK) in liver transplantation from brain death donors. *Rev Med Chil* 2014;142:1229-1237.
18. Hernandez N, Bessone F, Sanchez A, di Pace M, Brahm J, Zapata R, R AC, et al. Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. *Ann Hepatol* 2014;13:231-239.
19. Candia R, Ruiz A, Torres-Robles R, Chavez-Tapia N, Mendez-Sanchez N, Arrese M. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol* 2014.
20. Arab JP, Candia R, Zapata R, Munoz C, Arancibia JP, Poniachik J, Soza A, et al. Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review. *World J Gastroenterol* 2014;20:12182-12201.
21. Aguilar-Olivos N, Motola-Kuba M, Candia R, Arrese M, Mendez-Sanchez N, Uribe M, Chavez-Tapia NC. Hemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: Systematic review and meta-analysis. *Ann Hepatol* 2014;13:420-428.
22. Tejos R, Padilla O, Pizarro M, Solis N, Arab JP, Margozzini P, Miquel JF, et al. [Serum levels of alanine aminotransferase in Chilean population: analysis of results of the national health survey 2009-2010]. *Rev Med Chil* 2013;141:909-916.
23. Solis N, Pizarro M, Quintero P, Arab JP, Riquelme A, Padilla O, Carrasco G, et al. Effects of bile acid sequestration on hepatic steatosis in obese mice. *Ann Hepatol* 2013;13:105-112.
24. Perez-Gutierrez OZ, Hernandez-Rocha C, Candia-Balboa RA, Arrese MA, Benitez C, Brizuela-Alcantara DC, Mendez-Sanchez N, et al. Validation study

- of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population. *Ann Hepatol* 2013;12:416-424.
25. Mendez L, Lagoa M, Quiroga T, Margozzini P, Azocar L, Molina HR, Vera A, et al. [Prevalence of Gilbert syndrome and its genetic determinants in Chile]. *Rev Med Chil* 2013;141:1266-1274.
  26. Serrano Garcia C, Barrera F, Labbe P, Liberona J, Arrese M, Irarrazabal P, Tejos C, et al. [Quantification of visceral adipose tissue using magnetic resonance imaging compared with anthropometry, in type 2 diabetic patients]. *Rev Med Chil* 2012;140:1535-1543.
  27. Gabrielli M, Moisan F, Vidal M, Duarte I, Jimenez M, Izquierdo G, Dominguez P, et al. Steatotic livers. Can we use them in OLTx? Outcome data from a prospective baseline liver biopsy study. *Ann Hepatol* 2012;11:891-898.
  28. Candia R, Riquelme A, Baudrand R, Carvajal CA, Morales M, Solis N, Pizarro M, et al. Overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease. *Liver Int* 2012;32:392-399.
  29. Bessone F, Hernandez N, Davalos M, Parana R, Schinoni MI, Lizarzabal M, Kershenovich D, et al. Building a Spanish-Latin American network on drug induced liver injury: much to get from a joint collaborative initiative. *Ann Hepatol* 2012;11:544-549.
  30. Salech F, Valderrama S, Nervi B, Rodriguez JC, Oksenberg D, Koch A, Smok G, et al. Thalidomide for the treatment of metastatic hepatic epithelioid hemangioendothelioma: a case report with a long term follow-up. *Ann Hepatol* 2011;10:99-102.
  31. Espino A, Villagran A, Vollrath V, Hanckes P, Salas R, Farah A, Solis N, et al. Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease. *Ann Hepatol* 2011;10:493-501.
  32. Baudrand R, Dominguez JM, Carvajal CA, Riquelme A, Campino C, Macchiavello S, Bozinovic M, et al. Overexpression of hepatic 5alpha-reductase and 11beta-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue is associated with hyperinsulinemia in morbidly obese patients. *Metabolism* 2011;60:1775-1780.
  33. Amigo L, Husche C, Zanlungo S, Lutjohann D, Arrese M, Miquel JF, Rigotti A, et al. Cholecystectomy increases hepatic triglyceride content and very-low-density lipoproteins production in mice. *Liver Int* 2011;31:52-64.
  34. Vivanco M, Gabrielli M, Jarufe N, Humeres R, Rios H, Palacios JM, Zapata R, et al. Bridge therapy in hepatocellular carcinoma before liver transplantation: the experience of two Chilean centers. *Transplant Proc* 2010;42:296-298.
  35. Nazal L, Riquelme A, Solis N, Pizarro M, Escalona A, Burotto M, Mendez JI, et al. Hypoadiponectinemia and its association with liver fibrosis in morbidly obese patients. *Obes Surg* 2010;20:1400-1407.
  36. Gabrielli M, Vivanco M, Hepp J, Martinez J, Perez R, Guerra J, Arrese M, et al. Liver transplantation results for hepatocellular carcinoma in Chile. *Transplant Proc* 2010;42:299-301.

37. Baudrand R, Carvajal CA, Riquelme A, Morales M, Solis N, Pizarro M, Escalona A, et al. Overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients. *Obes Surg* 2010;20:77-83.
38. Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Perez-Ayuso RM, Gonzalez R, et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. *Liver Int* 2009;29:82-88.
39. Fickert P, Fuchsbichler A, Moustafa T, Wagner M, Zollner G, Halilbasic E, Stoger U, et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. *Am J Pathol* 2009;175:2392-2405.
40. Arab JP, Ramirez C, Munoz P, Pizarro M, Solis N, Riquelme A, Arrese M. Effects of Japanese herbal medicine Inchin-ko-to on endotoxin-induced cholestasis in the rat. *Ann Hepatol* 2009;8:228-233.
41. Arab JP, Pizarro M, Solis N, Sun H, Thevananther S, Arrese M. Mild hypothermia does not affect liver regeneration after partial hepatectomy in mice. *Liver Int* 2009;29:344-348.
42. Zuniga S, Molina H, Azocar L, Amigo L, Nervi F, Pimentel F, Jarufe N, et al. Ezetimibe prevents cholesterol gallstone formation in mice. *Liver Int* 2008;28:935-947.
43. Molina H, Azocar L, Ananthanarayanan M, Arrese M, Miquel JF. Localization of the Sodium-Taurocholate cotransporting polypeptide in membrane rafts and modulation of its activity by cholesterol in vitro. *Biochim Biophys Acta* 2008;1778:1283-1291.
44. Mellado P, Peredo P, Valenzuela R, Arrese M, Perez RM, Dominguez P, Guerra JF, et al. [Neurological complications following a liver transplantation: experience from a Chilean center]. *Rev Med Chil* 2008;136:1255-1263.
45. Riquelme A, Soza A, Pedreros C, Bustamante A, Valenzuela F, Otarola F, Abbott E, et al. Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile. *World J Gastroenterol* 2007;13:2967-2972.
46. Ibanez P, Solis N, Pizarro M, Aguayo G, Duarte I, Miquel JF, Accatino L, et al. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. *J Gastroenterol Hepatol* 2007;22:846-851.
47. Cerda C, Perez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir-Petermann T, Espinoza M, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. *J Hepatol* 2007;47:412-417.
48. Vial P, Riquelme A, Pizarro M, Solis N, Madariaga JA, Aguayo G, Duarte I, et al. Pentoxifylline does not prevent neither liver damage nor early profibrogenic events in a rat model of non-alcoholic steatohepatitis. *Ann Hepatol* 2006;5:25-29.
49. Riquelme A, Calvo M, Salech F, Valderrama S, Pattillo A, Arellano M, Arrese M, et al. Value of adenosine deaminase (ADA) in ascitic fluid for the diagnosis of tuberculous peritonitis: a meta-analysis. *J Clin Gastroenterol* 2006;40:705-710.

50. Soza A, Riquelme A, Gonzalez R, Alvarez M, Perez-Ayuso RM, Glasinovic JC, Arrese M. Increased orocecal transit time in patients with nonalcoholic fatty liver disease. *Dig Dis Sci* 2005;50:1136-1140.
51. Gonzalez R, Soza A, Hernandez V, Perez RM, Alvarez M, Morales A, Arellano M, et al. Incidence and prevalence of hepatitis C virus infection in Chile. *Ann Hepatol* 2005;4:127-130.
52. Boza C, Riquelme A, Ibanez L, Duarte I, Norero E, Viviani P, Soza A, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. *Obes Surg* 2005;15:1148-1153.
53. Soza A, Arrese M, Gonzalez R, Alvarez M, Perez RM, Cortes P, Patillo A, et al. Clinical and epidemiological features of 147 Chilean patients with chronic hepatitis C. *Ann Hepatol* 2004;3:146-151.
54. Pizarro M, Balasubramaniyan N, Solis N, Solar A, Duarte I, Miquel JF, Suchy FJ, et al. Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function. *Gut* 2004;53:1837-1843.
55. Pattillo JC, Kusanovic R, Salas P, Reyes J, Garcia-Huidobro I, Sanhueza M, Palma A, et al. [Outpatient laparoscopic cholecystectomy. Experience in 357 patients]. *Rev Med Chil* 2004;132:429-436.
56. Riquelme AJ, Calvo MA, Guzman AM, Depix MS, Garcia P, Perez C, Arrese M, et al. *Saccharomyces cerevisiae* fungemia after *Saccharomyces boulardii* treatment in immunocompromised patients. *J Clin Gastroenterol* 2003;36:41-43.
57. Moreno M, Molina H, Amigo L, Zanlungo S, Arrese M, Rigotti A, Miquel JF. Hepatic overexpression of caveolins increases bile salt secretion in mice. *Hepatology* 2003;38:1477-1488.
58. Arrese M, Trauner M, Ananthanarayanan M, Pizarro M, Solis N, Accatino L, Soroka C, et al. Down-regulation of the Na<sup>+</sup>/taurocholate cotransporting polypeptide during pregnancy in the rat. *J Hepatol* 2003;38:148-155.
59. Accatino L, Pizarro M, Solis N, Arrese M, Koenig CS. Bile secretory function after warm hepatic ischemia-reperfusion injury in the rat. *Liver Transpl* 2003;9:1199-1210.
60. Sun AQ, Arrese MA, Zeng L, Swaby I, Zhou MM, Suchy FJ. The rat liver Na<sup>(+)</sup>/bile acid cotransporter. Importance of the cytoplasmic tail to function and plasma membrane targeting. *J Biol Chem* 2001;276:6825-6833.
61. Xu G, Shneider BL, Shefer S, Nguyen LB, Batta AK, Tint GS, Arrese M, et al. Ileal bile acid transport regulates bile acid pool, synthesis, and plasma cholesterol levels differently in cholesterol-fed rats and rabbits. *J Lipid Res* 2000;41:298-304.
62. Accatino L, Pizarro M, Solis N, Arrese M, Vollrath V, Ananthanarayanan M, Chianale J, et al. Differential expression of canalicular membrane Ca<sup>2+</sup>/Mg<sup>(2+)</sup>-ecto-ATPase in estrogen-induced and obstructive cholestasis in the rat. *J Lab Clin Med* 2000;136:125-137.
63. Trauner M, Arrese M, Lee H, Boyer JL, Karpen SJ. Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors. *J Clin Invest* 1998;101:2092-2100.

64. Koepfel TA, Trauner M, Mennone A, Arrese M, Rios-Velez L, Boyer JL. Role of glutathione in hepatic bile formation during reperfusion after cold ischemia of the rat liver. *J Hepatol* 1998;28:812-819.
65. Coppola CP, Gosche JR, Arrese M, Ancowitz B, Madsen J, Vanderhoof J, Shneider BL. Molecular analysis of the adaptive response of intestinal bile acid transport after ileal resection in the rat. *Gastroenterology* 1998;115:1172-1178.
66. Arrese M, Trauner M, Sacchiero RJ, Crossman MW, Shneider BL. Neither intestinal sequestration of bile acids nor common bile duct ligation modulate the expression and function of the rat ileal bile acid transporter. *Hepatology* 1998;28:1081-1087.
67. Arrese M, Trauner M, Ananthanarayanan M, Boyer JL, Suchy FJ. Maternal cholestasis does not affect the ontogenic pattern of expression of the Na<sup>+</sup>/taurocholate cotransporting polypeptide (ntcp) in the fetal and neonatal rat liver. *Hepatology* 1998;28:789-795.
68. Trauner M, Arrese M, Soroka CJ, Ananthanarayanan M, Koepfel TA, Schlosser SF, Suchy FJ, et al. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. *Gastroenterology* 1997;113:255-264.
69. Rollan A, Giancaspero R, Arrese M, Figueroa C, Vollrath V, Schultz M, Duarte I, et al. Accuracy of invasive and noninvasive tests to diagnose *Helicobacter pylori* infection after antibiotic treatment. *Am J Gastroenterol* 1997;92:1268-1274.
70. Arrese M, Pizarro M, Solis N, Accatino L. Adaptive regulation of hepatic bile salt transport: role of bile salt hydrophobicity and microtubule-dependent vesicular pathway. *J Hepatol* 1997;26:694-702.
71. Reyes H, Ribalta J, Hernandez I, Arrese M, Pak N, Wells M, Kirsch RE. Is dietary erucic acid hepatotoxic in pregnancy? An experimental study in rats and hamsters. *Hepatology* 1995;21:1373-1379.
72. Arrese M, Pizarro M, Solis N, Koenig C, Accatino L. Enhanced biliary excretion of canalicular membrane enzymes in ethynylestradiol-induced cholestasis. Effects of ursodeoxycholic acid administration. *Biochem Pharmacol* 1995;50:1223-1232.
73. Andresen M, Dussillant G, Dougnac A, Arrese M, Arriagada D, Carlos Glasinovic J, Villarroel L. [Vital prognosis in severe acute hepatic failure. Value of the quantitative indexes of evaluation]. *Rev Med Chil* 1995;123:1373-1378.
74. Puglielli L, Amigo L, Arrese M, Nunez L, Rigotti A, Garrido J, Gonzalez S, et al. Protective role of biliary cholesterol and phospholipid lamellae against bile acid-induced cell damage. *Gastroenterology* 1994;107:244-254.
75. Andresen M, Arrese M, Dussillant G, Dougnac A, Campusano C, Glasinovic JC. [Multiple organ failure syndrome in fulminant hepatic failure]. *Rev Med Chil* 1994;122:661-666.
76. Wielandt AM, Pizarro M, Solis N, Arrese M, Accatino L. Postcholestatic alkaline phosphatase activity after relief of bile duct obstruction in the rat. *Hepatology* 1993;18:179-187.

77. Ribalta J, Reyes H, Gonzalez MC, Iglesias J, Arrese M, Poniachik J, Molina C, et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. *Hepatology* 1991;13:1084-1089.
78. Gonzalez MC, Reyes H, Arrese M, Figueroa D, Lorca B, Andresen M, Segovia N, et al. Intrahepatic cholestasis of pregnancy in twin pregnancies. *J Hepatol* 1989;9:84-90.

## Reviews (28)

1. Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of non-alcoholic fatty liver disease. *Annu. Rev. Pathol. Mech. Dis.* 2018 (in press)
2. Vargas JI, Arrese M, Shah V, Arab JP. Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects. *Current Hepatology Reports* 2017 (in press)
3. Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids & nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. *Hepatology*. 2017 Jan;65(1):350-362
4. Arrese M, Cabrera D, Kalergis AM, Feldstein AE. Innate Immunity and Inflammation in NAFLD/NASH. *Dig Dis Sci.* 2016 May;61(5):1294-303
5. Arab JP, Claro JC, Arancibia JP, Contreras J, Gómez F, Muñoz C, Nazal L, Roessler E, Wolff R, Arrese M, Benítez C. Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus. *World J Hepatol.* 2016 Sep 8;8(25):1075-86
6. Arrese M, Eguchi A, Feldstein AE. Circulating microRNAs: Emerging Biomarkers of Liver Disease. *Semin Liver Dis* 2015;35:43-54.
7. Rios JA, Cisternas P, Arrese M, Barja S, Inestrosa NC. Is Alzheimer's disease related to metabolic syndrome? A Wnt signaling conundrum. *Prog Neurobiol* 2014;121:125-146.
8. Lopez-Velazquez JA, Silva-Vidal KV, Ponciano-Rodriguez G, Chavez-Tapia NC, Arrese M, Uribe M, Mendez-Sanchez N. The prevalence of nonalcoholic fatty liver disease in the Americas. *Ann Hepatol* 2014;13:166-178.
9. Arrese M, Riquelme A, Soza A. Insulin resistance, hepatic steatosis and hepatitis C: a complex relationship with relevant clinical implications. *Ann Hepatol* 2010;9 Suppl:112-118
10. Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. *Biochim Biophys Acta* 2010;1801:299-310.
11. Soza A, Riquelme A, Arrese M. Routes of transmission of hepatitis C virus. *Ann Hepatol* 2010;9 Suppl:33.
12. Arrese M, Karpen SJ. Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases. *Clin Pharmacol Ther* 2010;87:473-478.

13. Von Bernhardt R, Zanlungo S, Arrese M, Arteaga A, Rigotti A. [The metabolic syndrome: from an aggravating condition to a pathogenic risk factor for chronic diseases]. *Rev Med Chil* 2010;138:1012-1019.
14. Hepp J, Zapata R, Buckel E, Martinez J, Uribe M, Diaz JC, Ferrario M, et al. [General considerations, indications and contraindications for liver transplantation in Chile: a multicenter consensus development document]. *Rev Med Chil* 2008;136:793-804.
15. Marin JJ, Macias RI, Briz O, Perez MJ, Blazquez AG, Arrese M, Serrano MA. Molecular bases of the fetal liver-placenta-maternal liver excretory pathway for cholephilic compounds. *Liver Int* 2008;28:435-454.
16. Arrese M, Macias RI, Briz O, Perez MJ, Marin JJ. Molecular pathogenesis of intrahepatic cholestasis of pregnancy. *Expert Rev Mol Med* 2008;10:e9.
17. Mendez-Sanchez N, Arrese M, Zamora-Valdes D, Uribe M. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. *Liver Int* 2007;27:423-433.
18. Mendez-Sanchez N, Arrese M, Zamora-Valdes D, Uribe M. Treating nonalcoholic fatty liver disease. *Liver Int* 2007;27:1157-1165.
19. Arrese M, Reyes H. Intrahepatic cholestasis of pregnancy: a past and present riddle. *Ann Hepatol* 2006;5:202-205.
20. Arrese M. Cholestasis during pregnancy: rare hepatic diseases unmasked by pregnancy. *Ann Hepatol* 2006;5:216-218.
21. Arrese M, Ananthanarayanan M. The bile salt export pump: molecular properties, function and regulation. *Pflugers Arch* 2004;449:123-131.
22. Arrese M, Trauner M. Molecular aspects of bile formation and cholestasis. *Trends Mol Med* 2003;9:558-564.
23. Arrese M, Accatino L. From blood to bile: recent advances in hepatobiliary transport. *Ann Hepatol* 2002;1:64-71.
24. Zanlungo S, Rigotti A, Arrese M. [Molecular biology and medicine: basic concepts]. *Rev Med Chil* 1999;127:839-847.
25. Zanlungo S, Arrese M, Rigotti A. [Molecular medicine: present and future]. *Rev Med Chil* 1999;127:982-988.
26. Arrese M. [Identification of molecular defects in liver diseases. Recent advances]. *Rev Med Chil* 1999;127:1112-1120.
27. Arrese M, Ananthanarayanan M, Suchy FJ. Hepatobiliary transport: molecular mechanisms of development and cholestasis. *Pediatr Res* 1998;44:141-147.
28. Arrese M, Accatino L. [Ursodeoxycholic acid in the treatment of cholestatic liver diseases]. *Rev Med Chil* 1993;121:439-446.

### **Invited editorials (5)**

1. Arrese M, Feldstein AE. NASH-Related Cirrhosis: An Occult Liver Disease Burden. *Hepatology Communications*, 2017;1:84-86
2. Quintero P, Arrese M. Nuclear control of inflammation and fibrosis in

- nonalcoholic steatohepatitis: therapeutic potential of dual peroxisome proliferator-activated receptor alpha/delta agonism. *Hepatology* 2013;58:1881-1884.
3. Nervi F, Arrese M. Cholecystectomy and NAFLD: does gallbladder removal have metabolic consequences? *Am J Gastroenterol* 2013;108:959-961.
  4. Arrese M. Burning hepatic fat: therapeutic potential for liver-specific thymomimetics in the treatment of nonalcoholic fatty liver disease. *Hepatology* 2009;49:348-351.
  5. Arrese M, Riquelme A. The value of serum adipokine measurement in non-alcoholic fatty liver disease. *Liver Int* 2009;29:1291-1293.

### **Commentaries (10)**

1. Obeticholic acid: expanding the therapeutic landscape of NASH. *Ann Hepatol*. 2015 May-Jun;14(3):430-2
2. Quintero P, Arrese M. Regulation of bile acid metabolism: new insights from inside. *Hepatology* 2013;58:1850-1853.
3. Arrese M. Nonalcoholic fatty liver disease: liver disease: an overlooked complication of diabetes mellitus. *Nat Rev Endocrinol* 2010;6:660-661.
4. Arab JP, Ramirez C, Arrese M. Early warning of liver disease in diabetics. *Ann Hepatol* 2010;9:307-309.
5. Arrese M, Miquel JF, Ananthanarayanan M. BetaKlotho: a new kid on the bile acid biosynthesis block. *Hepatology* 2006;43:191-193.
6. Arrese M, Karpen SJ. HNF-1 alpha: have bile acid transport genes found their "master"? *J Hepatol* 2002;36:142-145.
7. Arrese M, Karpen SJ. Bile acids regulate their own synthesis: the nuclear connection. *Gastroenterology* 2001;120:1557-1558
8. Arrese M, Karpen SJ. New horizons in the regulation of bile acid and lipid homeostasis: critical role of the nuclear receptor FXR as an intracellular bile acid sensor. *Gut* 2001;49:465-466
9. Arrese M, Ananthanarayanan M. Mice and men: are they bile-ologically different? *Hepatology* 2001;33:1551-1553.
10. Arrese MA, Crawford JM. Of plaques and stones: the SR-B1 (scavenger receptor class B, type 1). *Hepatology* 1997;26:1072-1074.

### **Case –reports and case-series (18)**

1. Bustamante V, Arab JP, Terc F, Poggi H, Goycoolea M, Arrese M, Quiroga T, Benítez C. Persistent elevation of aspartate aminotransferase (AST) due to the presence of macro-AST: Report of one case. *Rev Med Chil*. 2016 Aug;144(8):1078-1082

2. Soza A, Labbe P, Arrese M, Riquelme A, Barrera F, Benitez C, Huete A, et al. Mycobacterium abscessus pulmonary infection during hepatitis C treatment with telaprevir, peginterferon and ribavirin. *Ann Hepatol* 2015;14:132-136.
3. Arab JP, Vargas JI, Morales C, Arrese M Black hairy tongue during interferon therapy for hepatitis C. *Ann Hepatol*. 2015 May-Jun;14(3):414-5.
4. Martínez J, Besa S, Arab JP, Quintana JC, Regonesi C, Huete A, Jarufe N, Guerra JF, Benitez C, Arrese M, Benitez C. Gastrointestinal neuroendocrine tumor with unresectable liver metastases: an example of multimodal therapeutic approach. *Ann Hepatol*. 2015 Sep-Oct;14(5):752-5
5. Soza A, Labbe P, Arrese M, Riquelme A, Barrera F, Benitez C, Huete A, et al. Mycobacterium abscessus pulmonary infection during hepatitis C treatment with telaprevir, peginterferon and ribavirin. *Ann Hepatol* 2015;14:132-136.
6. Norero B, Perez-Ayuso RM, Duarte I, Ramirez P, Soza A, Arrese M, Benitez C. Portal hypertension and acute liver failure as uncommon manifestations of primary amyloidosis. *Ann Hepatol* 2013;13:142-149.
7. Benitez CE, Rey P, Zoroquiain P, Martinez J, Ramirez P, Arrese M, Perez-Ayuso RM, et al. Early-onset EBV-positive post-transplant plasmablastic lymphoma arising in a liver allograft: a case report and literature review. *Int J Surg Pathol* 2013;21:404-410.
8. Arab JP, Meneses L, Perez RM, Arrese M, Benitez C. Hepatic encephalopathy in a liver transplant recipient with stable liver function. *Hepatology* 2013;57:1672-1674.
9. Benitez C, Arancibia JP, Arrese M, Soza A, Dominguez P, Jarufe N, Martinez J, et al. Operational tolerance after liver transplantation, more common than we think: a case report. *Ann Hepatol* 2011;10:361-364.
10. Benitez C, Arrese M, Jorquera J, Godoy I, Contreras A, Loyola S, Dominguez P, et al. Successful treatment of severe hepatopulmonary syndrome with a sequential use of TIPS placement and liver transplantation. *Ann Hepatol* 2009;8:71-74.
11. Butte JM, Devaud N, Jarufe NP, Boza C, Perez G, Torres J, Perez-Ayuso RM, et al. Sleeve gastrectomy as treatment for severe obesity after orthotopic liver transplantation. *Obes Surg* 2007;17:1517-1519.
12. Jarufe N, Soza A, Perez-Ayuso RM, Poblete JA, Gonzalez R, Guajardo M, Hernandez V, et al. Successful liver transplantation and delivery in a woman with fulminant hepatic failure occurring during the second trimester of pregnancy. *Liver Int* 2006;26:494-497.
13. Riquelme A, Soza A, Nazal L, Martinez G, Kolbach M, Patillo A, Arellano JM, et al. Histological resolution of steatohepatitis after iron depletion. *Dig Dis Sci* 2004;49:1012-1015.
14. Soza A, Riquelme F, Alvarez M, Duarte I, Glasinovic JC, Arrese M. [Hepatotoxicity by amoxicillin/clavulanic acid: case report]. *Rev Med Chil* 1999;127:1487-1491.
15. Arrese M, Lopez F, Rossi R, Traipe E, Cruz F. Extrahepatic cholestasis attributable to tuberculous adenitis. *Am J Gastroenterol* 1997;92:912-913.

16. Arrese M, Ebel L, Hofmann E, Gaete P, Jara A, Cabrera K, Araos F, et al. [Miliary tuberculosis as a complication of BCG immunotherapy in cancer of the bladder. Case report]. *Rev Med Chil* 1992;120:910-913.
17. Arrese M, Castellon JM, Contreras G. [Eosinophilic pneumonia causing severe respiratory insufficiency. Clinical case]. *Rev Med Chil* 1991;119:299-302.
18. Seguel M, Arrese M, Perez C, Alvarez M, Labarca R, Veloso M. [Munchausen's syndrome: a study of 6 cases]. *Rev Med Chil* 1990;118:1090-1097.

### **Letters (3)**

1. Arrese M, Accatino L. Is intrahepatic cholestasis of pregnancy an MDR3-related disease? *Gastroenterology* 2003;125:1922-1923; author reply 1923-1924.
2. Andresen M, Arrese M, Dougnac A, Godoy J, Prat G, Chianale J. [GABA-benzodiazepine receptor complex: therapeutic role of benzodiazepine antagonists]. *Rev Med Chil* 1989;117:944-946.
3. Arrese MA. [Why undertake biomedical research in Chile? Response from a medical student]. *Rev Med Chil* 1987;115:1007-1008.

### **Essays (2)**

1. Arrese M. The liver in poetry: Neruda's 'Ode to the liver'. *Liver Int* 2008;28:901-905.
2. Arrese M. The liver in painting: a case of abstraction. *Liver Int* 2012;32:873-874.

### **BOOK CHAPTERS**

1. Arrese M, Pizarro M, Solís N, Accatino L. Pregnancy and hepatic transport: implications for the pathogenesis of intrahepatic cholestasis of pregnancy". In: "Bile Acids and Pregnancy". U. Leuschner, P.A. Berg, J. Holtmeier (eds.), Kluwer Academic Publishers, Dordrecht/Boston/Londres. Pp. 39-45, 2002
2. Arrese M, Ibañez P. Cholestasis. In: Weitz JC, Berger Z, Sabah S, Silva H. (eds.) *Digestive diseases: Diagnosis and treatment*. Editorial IKU. Santiago, Chile. 2003, pp. 170-177
3. Accatino L., Arrese M, Pizarro N, Solís. Mechanisms of liver ischemic reperfusion injury In: Mendez-Sanchez N, Uribe M (eds). *Current Concepts in Hepatology*, Masson-Doyma-Mexico SA, Ciudad de México 2003. pp: 283-288
4. Soza A, Martínez J, Pérez-Ayuso RM, Arrese M. "Acute Liver Failure". In: Bugeo G, Castillo L, Dougnac A. (eds) *Intensive Medicine*. Editorial Mediterráneo. 2005. Santiago, Chile.
5. Arrese M. Cholestasis. In: Weitz JC, Berger Z, Sabah S, Silva H. (eds.) *Digestive diseases: Diagnosis and treatment*. 2008. Editorial IKU. Santiago, Chile. pp. 250-258.
6. Arrese M, Arab Jp, Arancibia JP, Candia R, Riquelme A, Barrera F Liver Disease A neglected complication of Diabetes Mellitus. In: Bagchi D, Sreejayan N (eds)

- Nutritional and Therapeutic Interventions of Diabetes and Metabolic Syndrome (Elsevier/Academic Press) 2012 Pages 289-296
7. Arab JP, Glasinovic E, Arrese M. Cholestasis: pathophysiology and treatment. In: *Advances in Hepatology 2012* Tagle M, Bussalleu A (Eds.). Universidad Peruana Cayetano Heredia, 2012. pp 125-141
  8. Arab JP, Arrese M. Cholestasis. In: Weitz JC, Berger Z, Sabah S, Silva H. (eds.) *Digestive diseases: Diagnosis and treatment*. 2013. Editorial IKU. Santiago, Chile. pp. 291-298.
  9. Arrese M, Arab JP, Gana JC. Hígado graso no alcohólico. In: Gana JC, Harris P, Hodgson MI. (eds.) *Práctica Clínica en Gastroenterología, Hepatología y Nutrición Pediátrica*. Ediciones Universidad Católica; 2015. p. 523-530.
  10. Arab JP, Arrese M Hígado graso no alcohólico en paciente no obeso y no diabético. In: Tagle M. and Bussalleu A. (eds.). *Escenarios Clínicos Y Controversias: Hepatología 2015*. Universidad Peruana Cayetano Heredia Lima, Perú, pp. 141-147
  11. Norero B, Benítez C, Soza A, Arrese M. "Acute Liver Failure". In: Bugedo G, Castillo L, Romero C. (eds) *Intensive Medicine, Pathophysiology and Clinics*. Editorial Mediterráneo. 2015. Santiago, Chile.
  12. Ruiz A, Arab JP, Arrese M. Toxic cholestasis: mechanisms and practical management Cincal and Basic Concepts In *Modern Hepatology*. Mendez-Sanchez N (ed). McGraw-Hill/INTERAMERICANA EDITORES, Mexico city, Mexico. Pp 112-121
  13. Arrese M. Liver Disease in Pregnancy. In: Farreras-Valentí P, Rozman C, Cardellach-López F (eds.) *Farreras Rozman Internal Medicine Textbook (in spanish)* 18th edition, 2016 Elsevier, Spain, pp. 354-357